Moyamoya Biomarkers

Overview

Journal J Korean Neurosurg Soc

Date 2015 Jul 17

PMID 26180608

Citations 16

Authors

Edward R Smith

Affiliations

Soon will be listed here.

Abstract

Moyamoya disease (MMD) is an arteriopathy of the intracranial circulation predominantly affecting the branches of the internal carotid arteries. Heterogeneity in presentation, progression and response to therapy has prompted intense study to improve the diagnosis and prognosis of this disease. Recent progress in the development of moyamoya-related biomarkers has stimulated marked interest in this field. Biomarkers can be defined as biologically derived agents-such as specific molecules or unique patterns on imaging-that can identify the presence of disease or help to predict its course. This article reviews the current categories of biomarkers relevant to MMD-including proteins, cells and genes-along with potential limitations and applications for their use.

Citing Articles

Lectin-type oxidized LDL receptor-1 as a potential therapeutic target for cerebral cavernous malformations treatment.

Ashok K, Martinez T, Sesen J, Nasim S, Lang S, Heuer G Front Neurosci. 2024; 18:1442110.

PMID: 39234183 PMC: 11371587. DOI: 10.3389/fnins.2024.1442110.

Disease specific urinary biomarkers in the central nervous system.

Duggins-Warf M, Ghalali A, Sesen J, Martinez T, Fehnel K, Pineda S Sci Rep. 2023; 13(1):19244.

PMID: 37935834 PMC: 10630515. DOI: 10.1038/s41598-023-46763-z.

Cerebral Vasculopathy in Children with Neurofibromatosis Type 1.

Lehman L, Ullrich N Cancers (Basel). 2023; 15(20).

PMID: 37894478 PMC: 10605225. DOI: 10.3390/cancers15205111.

Physiological and pathophysiological mechanisms of the molecular and cellular biology of angiogenesis and inflammation in moyamoya angiopathy and related vascular diseases.

Dorschel K, Wanebo J Front Neurol. 2023; 14:661611.

PMID: 37273690 PMC: 10236939. DOI: 10.3389/fneur.2023.661611.

Bioinformatics analysis reveals the landscape of immune cell infiltration and novel immune-related biomarkers in moyamoya disease.

Cao L, Ai Y, Dong Y, Li D, Wang H, Sun K Front Genet. 2023; 14:1101612.

PMID: 37265961 PMC: 10230076. DOI: 10.3389/fgene.2023.1101612.

References

Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M . Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg. 1998; 89(4):623-9. DOI: 10.3171/jns.1998.89.4.0623. View

Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M . A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet. 2004; 49(5):278-81. DOI: 10.1007/s10038-004-0143-6. View

Roach E, Golomb M, Adams R, Biller J, Daniels S, deVeber G . Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008; 39(9):2644-91. DOI: 10.1161/STROKEAHA.108.189696. View

Kashiwagi S, Yamashita T, Katoh S, Kitahara T, Nakashima K, Yasuhara S . Regression of moyamoya vessels and hemodynamic changes after successful revascularization in childhood moyamoya disease. Acta Neurol Scand Suppl. 1996; 166:85-8. DOI: 10.1111/j.1600-0404.1996.tb00557.x. View

Munot P, Saunders D, Milewicz D, Regalado E, Ostergaard J, Braun K . A novel distinctive cerebrovascular phenotype is associated with heterozygous Arg179 ACTA2 mutations. Brain. 2012; 135(Pt 8):2506-14. PMC: 3407424. DOI: 10.1093/brain/aws172. View

Bernard T, Fenton L, Apkon S, Boada R, Wilkening G, Wilkinson C . Biomarkers of hypercoagulability and inflammation in childhood-onset arterial ischemic stroke. J Pediatr. 2009; 156(4):651-6. DOI: 10.1016/j.jpeds.2009.10.034. View

Choi H, Phi J, Paeng J, Kim S, Lee Y, Jeong J . Imaging of integrin α(V)β(3) expression using (68)Ga-RGD positron emission tomography in pediatric cerebral infarct. Mol Imaging. 2013; 12(4):213-7. View

Kang H, Moon Y, Kim Y, Park W, Park A, Wang K . Smooth-muscle progenitor cells isolated from patients with moyamoya disease: novel experimental cell model. J Neurosurg. 2013; 120(2):415-25. DOI: 10.3171/2013.9.JNS131000. View

Kainth D, Chaudhry S, Kainth H, Suri F, Qureshi A . Prevalence and characteristics of concurrent down syndrome in patients with moyamoya disease. Neurosurgery. 2012; 72(2):210-5. DOI: 10.1227/NEU.0b013e31827b9beb. View

10.

Amano T, Inoha S, Wu C, Matsushima T, Ikezaki K . Serum alpha1-antitrypsin level and phenotype associated with familial moyamoya disease. Childs Nerv Syst. 2003; 19(9):655-8. DOI: 10.1007/s00381-003-0799-9. View

11.

Kennedy B, McDowell M, Yang P, Wilson C, Li S, Hankinson T . Pial synangiosis for moyamoya syndrome in children with sickle cell anemia: a comprehensive review of reported cases. Neurosurg Focus. 2014; 36(1):E12. DOI: 10.3171/2013.10.FOCUS13405. View

12.

Koss M, Scott R, Irons M, Smith E, Ullrich N . Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013; 11(4):417-25. DOI: 10.3171/2012.12.PEDS12281. View

13.

Kawashima M, Noguchi T, Takase Y, Nakahara Y, Matsushima T . Decrease in leptomeningeal ivy sign on fluid-attenuated inversion recovery images after cerebral revascularization in patients with Moyamoya disease. AJNR Am J Neuroradiol. 2010; 31(9):1713-8. PMC: 7964983. DOI: 10.3174/ajnr.A2124. View

14.

Jung K, Chu K, Lee S, Park H, Kim D, Kim J . Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab. 2008; 28(11):1795-803. DOI: 10.1038/jcbfm.2008.67. View

15.

Lin N, Baird L, Koss M, Kopecky K, Gone E, Ullrich N . Discovery of asymptomatic moyamoya arteriopathy in pediatric syndromic populations: radiographic and clinical progression. Neurosurg Focus. 2011; 31(6):E6. DOI: 10.3171/2011.10.FOCUS11228. View

16.

Qaiser R, Scott R, Smith E . Identification of an association between Robinow syndrome and moyamoya. Pediatr Neurosurg. 2009; 45(1):69-72. DOI: 10.1159/000204907. View

17.

Ni G, Liu W, Huang X, Zhu S, Yue X, Chen Z . Increased levels of circulating SDF-1α and CD34+ CXCR4+ cells in patients with moyamoya disease. Eur J Neurol. 2011; 18(11):1304-9. DOI: 10.1111/j.1468-1331.2011.03393.x. View

18.

Codd P, Scott R, Smith E . Seckel syndrome and moyamoya. J Neurosurg Pediatr. 2009; 3(4):320-4. DOI: 10.3171/2008.12.PEDS08205. View

19.

Yamada M, Fujii K, Fukui M . [Clinical features and outcomes in patients with asymptomatic moyamoya disease--from the results of nation-wide questionnaire survey]. No Shinkei Geka. 2005; 33(4):337-42. View

20.

Yanagawa Y, Sugiura T, Suzuki K, Okada Y . Moyamoya disease associated with positive findings for rheumatoid factor and myeloperoxidase-anti-neutrophil cytoplasmic antibody. West Indian Med J. 2007; 56(3):282-4. DOI: 10.1590/s0043-31442007000300019. View